Mechanisms of eosinophil-associated inflammation

Journal of Allergy and Clinical Immunology

Volumn 105, Issue 4, 2000, Pages 651-663

  Gleich, Gerald J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bronchial asthma; Eosinophil; IL 5; Immunity; Localization; Ribonuclease; Virus

Indexed keywords

CHEMOATTRACTANT; INTERLEUKIN 5; MUSCARINIC M2 RECEPTOR;

ANAPHYLAXIS; ASTHMA; BONE MARROW CELL; BRONCHUS HYPERREACTIVITY; CELL MATURATION; EFFECTOR CELL; ENDOTHELIUM CELL; ENZYME LOCALIZATION; EOSINOPHIL; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY;

EID: 0034049677     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.105712     Document Type: Article

References (111)

1. 1. Bronchial asthma. Fact sheet No. 206, December 1998. Available at: http://www.who.int/inf-fs/en/fact206.html. Accessed December 23, 1999.
2. 2. Kita H, Adolphson CR, Gleich GJ. Biology of eosinophils. In: Middleton E Jr, Reed CE, Ellis, EF, Adkinson NF Jr, Yunginger JW, Busse WW, editors. Allergy: principles and practice. 5th ed. St Louis: Mosby; 1998. p 242-60.
3. + cells from asthmatic subjects: a novel marker of progenitor cell commitment towards eosinophilic differentiation. J Clin Invest 1997;100:2466-75.
4. 4. Yoshida T, Ikuta K, Sugaya H, Maki K, Takagi M, Kanazawa H, et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5Rα-deficient mice. Immunity 1996;4:483-94.
5. 5. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79: 3101-9.
6. 6. Herndon FJ, Kayes SG. Depletion of eosinophils by anti-IL-5 monoclonal antibody treatment of mice infected with Trichinella spiralis does not alter parasite burden or immunologic resistance to reinfection. J Immunol 1992;149:3642-7.
7. 7. Sher A, Coffman RL, Hieny S, Scott P, Cheever AW. Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci U S A 1990;87:61-5.
8. 8. Nishinakamura R, Miyajima A, Mee PJ, Tybulewicz VLJ, Murray R. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 1996;88:2458-64.
9. 9. Plager DA, Loegering DA, Weiler DA, Checkel JL, Wagner JM, Clarke NJ, et al. A novel and highly divergent homolog of human eosinophil granule major basic protein. J Biol Chem 1999;274:14464-73.
10. 10. Barker RL, Gleich GJ, Pease LR. Acidic precursor revealed in human eosinophil granule major basic protein cDNA. J Exp Med 1988;168:1493-8.
11. 11. Popken-Harris P, McGrogan M, Loegering DA, Checkel JL, Kubo H, Thomas LL, et al. Expression, purification, and characterization of the recombinant proform of eosinophil granule major basic protein. J Immunol 1995;155:1472-80.
12. 12. Popken Harris P, Checkel J, Loegering D, Madden B, Springett M, Kephart G, et al. Regulation and processing of a precursor form of eosinophil granule major basic protein (proMBP) in differentiating eosinophils. Blood 1998;92:623-31.
13. 13. Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ, Rankin SM. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med 1998;188:1621-32.
14. 14. Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 1998;91:2240-8.
15. 15. Kim Y-K, Uno M, Hamilos DL, Beck L, Bochner B, Schleimer R, et al. Immunolocalization of CD34 in nasal polyposis: effect of topical corticosteroids. Am J Respir Cell Mol Biol 1999;20:388-97.
16. 16. Robinson SD, Frenette PS, Rayburn H, Cummiskey M, Ullman-Cullere M, Wagner DD, et al. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci U S A 1999;96:11452-7.
17. 17. Bochner BS, Sterbinsky SA, Bickel CA, Werfel S, Newman W. Differences between human eosinophils and neutrophils in the function and expression of sialic acid-containing counterligands for E-selectin. J Immunol 1994;152:774-82.
18. 18. Sriramarao P, Norton CR, Borgstrom P, DiScipio EG, Wolitzky BA, Broide DA. E-selectin preferentially supports neutrophil but not eosinophil rolling under conditions of flow in vitro and in vivo. J Immunol 1996;157:4672-80.
19. 19. Dobrina A, Menegazzi R, Carlos TM, Nardon E, Cramer R, Zacchi T, et al. Mechanisms of eosinophil adherence to cultured vascular endothelial cells: eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. J Clin Invest 1991;88:20-6.
20. 20. Bochner BS, Luscinskas FW, Gimbrone MA Jr. Newman W, Sterbinsky SA, Derse-Anthony CP, et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991;173:1553-7.
21. 21. Patel KD. Eosinophil tethering to interleukin-4-activated endothelial cells requires both P-selectin and vascular cell adhesion molecule-1. Blood 1998;92:3904-11.
22. 4 integrins mediate initial attachment, and E-selectin mediates rolling. J Immunol 1999;163:343-50.
23. 23. Broide DH, Humber D, Sriramarao P. Inhibition of eosinophil rolling and recruitment in P-selectin-and intracellular adhesion molecule-1-deficient mice. Blood 1998;91:2847-56.
24. 4 integrin. J Immunol 1999;163:3441-8.
25. 25. Rothenberg ME, Luster AD, Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cell and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci U S A 1995;92:8960-4.
26. 26. Sanz M-J, Ponath PD, Mackay CR, Newman W, Miyasaka M, Tamatani T, et al. Human eotaxin induces alpha and beta(2) integrin-dependent eosinophil accumulation in rat skin in vivo: delayed generation of eotaxin in response to IL-4. J Immunol 1998;160:3569-76.
27. 27. DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999;162:1127-36.
28. 28. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I: C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995;181:2119-27.
29. 29. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1994;179:881-7.
30. 30. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-56.
31. 31. Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M, et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998;232:418-25.
32. 32. Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99:1767-73.
33. 33. Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159:4593-601.
34. 34. Ghaffar O, Hamid Q, Renzi PM, Allakhverdi Z, Molet S, Hogg JC, et al. Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells. Am J Respir Crit Care Med 1999;159:1933-42.
35. 35. Teran LM, Mochizuki M, Bartels J, Valencia EL, Nakajima T, Hirai K, et al. Th1-and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol 1999;20:777-86.
36. 36. Mochizuki M, Bartels J, Mallet AI, Christophers E, Schroder JM. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998;160:60-8.
37. 37. Li L, Xia Y, Nguyen A, Lai YH, Feng L, Mossman TR, et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999;162:2477-87.
38. 38. White JR, Imburgia C, Dul E, Appelbaum E, O'Donnell K, O'Shannessy DJ, et al. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 1997;62:667-75.
39. 39. Shinkai A, Yoshisue H, Koike M, Shoji E, Nakagawa S, Saito A, et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999;163:1602-10.
40. 40. Ohno I, Ohtani H, Nitta Y, Suzuki J, Hoshi H, Honma M, et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997;16:212-9.
41. 41. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Transmigration of eosinophils through basement membrane components in vitro: synergistic effects of platelet-activating factor and eosinophil-active cytokines. Am J Respir Cell Mol Biol 1997;16:455-63.
42. 42. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol 1997;17:519-28.
43. 43. Kumagai K, Ohno I, Okada S, Ohkawara Y, Suzuki K, Shinya T, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 1999;162:4212-9.
44. 44. Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367:183-6.
45. 45. de Andres B, Rakasz E, Hagen M, McCormick ML, Mueller AL, Elliot D, et al. Lack of Fe-ε receptors on murine eosinophils: implications for the functional significance of elevated IgE and eosinophils in parasitic infections. Blood 1997;89:3826-36.
46. 46. Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, et al. Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 1999;162:6901-11.
47. 47. Seminario M-C, Saini SS, MacGlashan DW Jr, Bochner BS. Intracellular expression and release of FcεRIα by human eosinophils. J Immunol 1999;162:6893-900.
48. 48. Kim J-T, Schimming AW, Kita H. Ligation of FcγRII (CD32) pivotally regulates survival of human eosinophils. J Immunol 1999;162:4253-9.
49. 49. Motegi Y, Kita H. Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils. J Immunol 1998;161:4340-6.
50. 50. Horie S, Kita H. CD11b/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet-activating factor. J Immunol 1994;152:5457-67.
51. 2 integrin in the activation of eosinophils stimulated by IgG. J Immunol 1995;155:2631-41.
52. 52. Nagata M, Sedgwick JB, Kita H, Busse WW. Granulocyte macrophage colony-stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil function. Am J Respir Cell Mol Biol 1998;19:158-66.
53. 53. Bartemes KR, McKinney S, Gleich GJ, Kita H. Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG. J Immunol 1999;162:2982-9.
54. 54. Bozza PT, Yu W, Penrose JF, Morgan ES, Dvorak AM, Weller PF. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med 1997;186:909-20.
55. 55. Hozawa S, Haruta Y, Ishioka S, Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med 1995;152:1198-202.
56. 56. Gleich GJ, Adolphson CR. The eosinophil and bronchial asthma: evidence for a critical role of eosinophils in pathophysiology. In: Sanderson CJ, editor. Interleukin-5: from molecule to drug target for asthma. Vol 125. New York: Marcel Dekker; 1998. p 1-37.
57. 57. Frigas E, Loegering DA, Solley GO, Farrow GM, Gleich GJ. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc 1981;56:345-53.
58. 58. Minnicozzi M, Durán WN, Gleich GJ, Egan RW. Eosinophil granule proteins increase microvascular macromolecular transport in the hamster check pouch. J Immunol 1994;153:2664-70.
59. 59. Filley WV, Holley KE, Kephart GM, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982;2:11-6.
60. 60. Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988;137:62-9.
61. 61. Gundel RH, Gerritsen ME, Gleich GJ, Wegner CD. Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in primates. J Appl Physiol 1990;68:779-86.
62. 62. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991;87:1470-3.
63. 63. Coyle AJ, Perretti F, Manzini S, Irvin CG. Cationic protein-induced sensory nerve activation: role of substance P in airway hyperresponsiveness and plasma protein extravasation. J Clin Iinvest 1994;94:2301-6.
64. 64. Coyle AJ, Ackerman SJ, Burch R, Proud D, Irvin CG. Human eosinophil major basic protein and synthetic polycations induce airway responsiveness in vivo dependent upon bradykinin generation. J Clin Invest 1995;95:1735-40.
65. 65. Flavahan NA, Slifman NR, Gleich GJ, Vanhoutte PM. Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle: role of the epithelium. Am Rev Respir Dis 1988;138:685-8.
66. 66. White SR, Ohno S, Munoz NM, Gleich GJ, Abrahams C, Solway J, et al. Epithelium-dependent contraction of airway smooth muscle caused by eosinophil MBP. Am J Physiol 1990;259:L294-303.
67. 67. Lee JJ, Denzler KL, Farmer SC, Crosby JR, Lee NA. Eosinophil major basic protein (mMBP) knockout mice: ova-induced airway hyper-reactivity is contingent upon the presence of mMPB [abstract]. Am J Respir Crit Care Med 1999;159:A756.
68. 68. Costello RW, Fryer AD. Cholinergic mechanisms in asthma. In: Barnes PJ, Grunestein MM, Leff AR, Woolcock AJ, editors. Asthma. Philadelphia: Lippincott-Raven; 1997. p 965-84.
69. 69. Roffel AF, Elzinga CR, Zaagsma J. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990;3:47-51.
70. 70. Elbon CL, Jacoby DB, Fryer AD. Pretreatment with an antibody to IL-5 preserves the function of pulmonary M2 muscarinic receptors in antigen challenged guinea-pigs. Am J Respir Cell Mol Biol 1995;12:320-8.
71. 71. Fryer AD, Costello RW, Yost BL, Lobb RR, Tedder TF, Steeber AS, et al. Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways. J Clin Invest 1997;99:2036-44.
72. 2 muscarinic receptor function. Am J Physiol 1997;273:L93-103.
73. 73. Jacoby DB, Gleich GJ, Fryer AD. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 1993;91:1314-8.
74. 74. Fryer AD, Jacoby DB. Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. J Clin Invest 1992;90:2292-8.
75. 75. Lefort J, Nahori MA, Ruffie C, Vargaftig BB, Pretolani M. In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs. J Clin Invest 1996;97:1117-21.
76. 76. Evans CM, Jacoby DB, Gleich GJ, Fryer AD, Costello RW. Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 receptor function in antigen-challenged guinea pigs. J Clin Invest 1997;110:2254-62.
77. 77. Costello RW, Evans CM, Yost BL, Belmonte KE, Gleich GJ, Jacoby DB, et al. Antigen-induced hyperreactivity to histamine: role of the vagus nerves and eosinophils. Am J Physiol 1999;276:L709-14.
78. 78. Fryer AD, Adamko DJ, Yost BL, Jacoby DB. Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci 1999;64:449-55.
79. 79. Busse WW, Gern JE. Viruses in asthma. J Allergy Clin Immunol 1997;100:147-50.
80. 80. Calhoun WJ, Dick E, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994;94:2200-8.
81. 81. Schwarze J, Hamelmann E, Bradley KL, Takeda K. Gelfand EW. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest 1997;100:226-33.
82. 82. Schwarze J, Cieslewicz G, Hamelmann E, Joetham A, Shultz LD, Lamers MC, et al. IL-5 and eosinophils are essential for the development of airway hyperresponsiveness following acute respiratory syncytial virus infection. J Immunol 1999;162:2997-3004.
83. 83. Schwarze J, Cieslewicz G, Joetham A, Ikemura T, Hamelmann E, Gelfand EW. CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J Immunol 1999;162:4207-11.
84. 2 muscarinic receptor dysfunction, and antiviral effects. J Exp Med 1999;190:1465-77.
85. 85. Coyle AJ, Erard F, Bertrand C, Walti S, Pircher H, Le Gros G. Virus-specific CDS+ cells can switch to interleukin 5 production and induce airway eosinophilia. J Exp Med 1995;181:1229-33.
86. 86. Jacoby DB, Xiao HQ, Lee NH, Chan-Li Y, Fryer AD. Virus-and interferon-induced loss of inhibitory M-2 muscarine receptor function and gene expression in cultured airway parasympathetic neurons. J Clin Invest 1998;102:242-8.
87. 87. Slifman NR, Loegering DA, McKean DJ, Gleich GJ. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 1986;137:2913-7.
88. 88. Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A 1986;83:3146-50.
89. 89. Rosenberg HF, Tenen DG, Ackerman SJ. Molecular cloning of the human eosinophil-derived neurotoxin: a member of the ribonuclease gene family. Proc Natl Acad Sci U S A 1989;86:4460-4.
90. 90. Hamann KJ, Barker RL, Loegering DA, Pease LR, Gleich GJ. Sequence of human eosinophil-derived neurotoxin cDNA: identity of deduced amino acid sequence with human nonsecretory ribonucleases. Gene 1989;83:161-7.
91. 91. Rosenberg HF, Tenen DG, Ackerman SJ. Human eosinophil cationic protein: molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med 1989;170:163-71.
92. 92. Barker RL, Loegering DA, Ten RM, Hamann KJ, Pease LR, Gleich GJ. Eosinophil cationic protein cDNA: comparison with other toxic cationic proteins and ribonucleases. J Immunol 1989;143:952-5.
93. 93. Hamann KJ, Ten RM, Loegering DA, Jenkins RB, Heise MT, Schad CR, et al. Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: evidence for intronless coding sequences in the ribonuclease gene superfamily. Genomics 1990;7:535-46.
94. 94. Rosenberg HF, Dyer KD, Tiffany HL, Gonzalez M. Rapid evolution of a unique family of primate ribonuclease genes. Nat Genet 1995;10:219-23.
95. 95. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998;177:1458-64.
96. 96. Domachowske JB, Bonville CA, Dyer KD, Rosenberg HF. Evolution of antiviral activity in the ribonuclease A gene superfamily: evidence for a specific interaction between eosinophil-derived neurotoxin (EDN/RNase 2) and respiratory syncytial virus. Nucleic Acids Res 1998;26:5327-32.
97. 97. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein RNase 3 is another RNaseA-family ribonuclease with direct antiviral activitiy. Nucleic Acids Res 1998;26:3358-63.
98. 98. Becker S, Reed W, Henderson RW, Noah TL. RSV infection of airway epithelial cells causes production of the beta-chemokine RANTES. Am J Physiol 1997;272:L512-20.
99. 99. Saito T, Deskin RW, Casola A, Haeberle H, Olszewska B, Ernst PB, et al. Respiratory syncytial virus induced selective production of the chemokine RANTES by upper airway epithelial cells. J Infect Dis 1997;175:497-504.
100. 100. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytial virus infection induces expression of macrophage inflammatory protein 1-alpha (MIP-1-alpha) in the human lower respiratory tract in vivo: association with eosinophil recruitment and degranulation. Am J Respir Crit Care Med 1999;159:1918-24.
101. 101. Kimpen JL, Garofalo R, Welliver RC, Ogra PL. Activation of human eosinophils by respiratory syncytial virus. Pediatr Res 1992;32:160-4.
102. 102. Garofalo R, Kimpen JLL, Welliver RC, Ogra PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 1992;120:28-32.
103. 103. Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA, et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998;63:715-22.
104. 104. Nakajima H, Loegering DA, Kita H, Kephart GM, Gleich GJ. Reactivity of monoclonal antibodies EG1 and EG2 with eosinophils and their granule proteins. J Leukoc Biol 1999;66:447-54.
105. 105. Smith LJ. The prospects for long-term intervention in asthma with antileukotrienes. Clin Exp Allergy 1998;28(5 Suppl):154-63.
106. 106. Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999;30:71-8.
107. 107. Barker RL, Gundel RH, Gleich GJ, Checkel JL, Loegering DA, Pease LR, et al. Acidic polyamino acids inhibit human eosinophil granule major basic protein toxicity: evidence of a functional role for proMBP. J Clin Invest 1991;88:798-805.
108. 108. Hunt LW, Swedlund HA, Gleich GJ. Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin Proc 1996;71:361-8.
109. 109. Hunt LW, Frigas EF, Butterfield JH, Li JT, Patel A, Kita H, et al. Nebulized lidocaine prevents deterioration of pulmonary function following withdrawal of inhaled glucocorticoids [abstract]. Am J Respir Crit Care Med 1999;159:A644.
110. 110. Milgrom H, Frick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-73.
111. 111. Butterfield JH, Gleich GJ. Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994; 121:648-53.